HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH?

Ann Oncol. 2012 May;23(5):1371-1372. doi: 10.1093/annonc/mds064. Epub 2012 Mar 12.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / pathology
  • Carcinoma / diagnosis*
  • Carcinoma / genetics
  • Carcinoma / metabolism*
  • Carcinoma / pathology
  • Female
  • Gene Amplification / physiology
  • Gene Frequency
  • Humans
  • In Situ Hybridization, Fluorescence / statistics & numerical data*
  • Molecular Targeted Therapy / methods
  • Molecular Targeted Therapy / statistics & numerical data
  • Monitoring, Physiologic / methods
  • Neoplasm Invasiveness
  • Prognosis
  • Receptor, ErbB-2 / antagonists & inhibitors
  • Receptor, ErbB-2 / genetics
  • Receptor, ErbB-2 / metabolism*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab